Minapharm Pharmaceuticals

Start of operation of MINAPHARM and building of MINAPHARM factory. MINAPHARM is re-established as a multi-alliance company with worldwide links to the pharmaceutical industry. MINAPHARM differentiates its portfolio into a specialty pharmaceutical company with dedicated lines in gastroenterology, cardiology, orthopedics and uro-gynaecology. Operation of Rhein-Minapharm uniquely dedicated to the development and manufacturing of therapeutic proteins, using different eukaryotic expression systems (yeast and mammalian cell culture). MINAPHARM is launching the first mammalian-derived product Gonapure, recombinant human FSH. As a continuation of Minapharm unique series of "Expert Panel",. We are leading a transition towards high-value biologicals in our developing markets, while expanding a robust small-molecule setup in a business model that represents a far departure from existing regional models. MINAPHARM is constantly demonstrating its ability to achieve the balance between Innovation and Affordability, hence, facing the most complex challenges of unmet medical needs in emerging countries.